OBJECTIVE: Hyperhomocysteinemia and B-vitamin deficiency may be treatable risk factors for cognitive impairment and decline. Hyperhomocysteinemia, cognitive impairment, and depression are all common in individuals with kidney disease, including kidney transplant recipients. Accordingly, we assessed the prevalence of cognitive impairment and depressive symptoms in transplant recipients and their association with kidney function, plasma total homocysteine, and B-vitamin concentrations. SETTING: Cross-sectional analysis of baseline data from the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) Ancillary Cognitive Trial (FACT), which included 183 participants in FAVORIT who underwent detailed neuropsychological assessment before the study intervention. RESULTS: The mean age was 54.0 ± 9.5 years (range: 7 to 386 months). Men comprised 55.2% of the cohort, and the mean time between the current transplant and cognitive testing was 7.0 ± 5.8 years. Twenty-four percent of participants reported neurological or psychiatric complaints, and 30% exhibited symptoms of mild to severe depression. Testing revealed evidence of significant and selective deficits in this population: 33% performed more than 1 standard deviation (SD) below normed means on a memory test, 58% fell lower than 1 SD below the norms on a test of attention and mental processing speed, and 33% to 42% fell lower than 1 SD below the norms on several tests of executive function. Lower estimated glomerular filtration rate and lower folate were associated with poorer performance on tests of memory and executive function. CONCLUSIONS: These observations confirm previous reports of mood and cognitive impairments in adult kidney transplant recipients. Further research is needed to determine the benefit of B-vitamin supplementation and other interventions in this patient population. Copyright Â
OBJECTIVE:Hyperhomocysteinemia and B-vitamin deficiency may be treatable risk factors for cognitive impairment and decline. Hyperhomocysteinemia, cognitive impairment, and depression are all common in individuals with kidney disease, including kidney transplant recipients. Accordingly, we assessed the prevalence of cognitive impairment and depressive symptoms in transplant recipients and their association with kidney function, plasma total homocysteine, and B-vitamin concentrations. SETTING: Cross-sectional analysis of baseline data from the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) Ancillary Cognitive Trial (FACT), which included 183 participants in FAVORIT who underwent detailed neuropsychological assessment before the study intervention. RESULTS: The mean age was 54.0 ± 9.5 years (range: 7 to 386 months). Men comprised 55.2% of the cohort, and the mean time between the current transplant and cognitive testing was 7.0 ± 5.8 years. Twenty-four percent of participants reported neurological or psychiatric complaints, and 30% exhibited symptoms of mild to severe depression. Testing revealed evidence of significant and selective deficits in this population: 33% performed more than 1 standard deviation (SD) below normed means on a memory test, 58% fell lower than 1 SD below the norms on a test of attention and mental processing speed, and 33% to 42% fell lower than 1 SD below the norms on several tests of executive function. Lower estimated glomerular filtration rate and lower folate were associated with poorer performance on tests of memory and executive function. CONCLUSIONS: These observations confirm previous reports of mood and cognitive impairments in adult kidney transplant recipients. Further research is needed to determine the benefit of B-vitamin supplementation and other interventions in this patient population. Copyright Â
Authors: A S Levey; J A Beto; B E Coronado; G Eknoyan; R N Foley; B L Kasiske; M J Klag; L U Mailloux; C L Manske; K B Meyer; P S Parfrey; M A Pfeffer; N K Wenger; P W Wilson; J T Wright Journal: Am J Kidney Dis Date: 1998-11 Impact factor: 8.860
Authors: Christopher B Brady; J Michael Gaziano; Roberta A Cxypoliski; Peter D Guarino; James S Kaufman; Stuart R Warren; Pamela Hartigan; David S Goldfarb; Rex L Jamison Journal: Am J Kidney Dis Date: 2009-07-23 Impact factor: 8.860
Authors: Charalambos Antoniades; Cheerag Shirodaria; Paul Leeson; Otto A Baarholm; Tim Van-Assche; Colin Cunnington; Ravi Pillai; Chandi Ratnatunga; Dimitris Tousoulis; Christodoulos Stefanadis; Helga Refsum; Keith M Channon Journal: Circulation Date: 2009-04-27 Impact factor: 29.690
Authors: Krista L Lentine; Abhijit S Naik; Rosemary Ouseph; Zidong Zhang; David A Axelrod; Dorry L Segev; Vikas R Dharnidharka; Daniel C Brennan; Henry Randall; Raj Gadi; Ngan N Lam; Gregory P Hess; Bertram L Kasiske; Mark A Schnitzler Journal: Transpl Int Date: 2017-08-03 Impact factor: 3.782
Authors: Nadia M Chu; Alden L Gross; Ashton A Shaffer; Christine E Haugen; Silas P Norman; Qian-Li Xue; A Richey Sharrett; Michelle Carlson; Karen Bandeen-Roche; Dorry L Segev; Mara A McAdams-DeMarco Journal: J Am Soc Nephrol Date: 2019-07-12 Impact factor: 10.121
Authors: Jin Zhou; Jie Li; Daniel M Rosenbaum; Jian Zhuang; Carrie Poon; Pu Qin; Katrina Rivera; John Lepore; Robert N Willette; Erding Hu; Frank C Barone Journal: PLoS One Date: 2017-09-07 Impact factor: 3.240
Authors: Marit S van Sandwijk; Ineke J M Ten Berge; Matthan W A Caan; Marco Düring; Willem A van Gool; Charles B L M Majoie; Henk-Jan M M Mutsaerts; Ben A Schmand; Anouk Schrantee; Leo M J de Sonneville; Frederike J Bemelman Journal: Transplant Direct Date: 2020-02-10